An outbreak of hantavirus occurred on a luxury cruise ship recently, drawing attention to the incurable disease. Hantavirus is uncommon and usually not transmissible between people. Infections typically occur through contact with contaminated objects, food, or air containing rodent waste. Although rare, transmission can also happen through rodent bites.
The disease can be fatal, with no specific treatment available. Efforts are underway globally to develop a vaccine for hantavirus, but progress is in the early stages, and widespread availability may take years. Some hantaviruses in Europe and Asia can cause hemorrhagic fever with renal syndrome, affecting the kidneys and potentially leading to fatal bleeding complications.
In the Americas, certain hantaviruses can result in hantavirus pulmonary syndrome, predominantly impacting the lungs and causing death in around 40% of cases. Canada has recorded 168 hantavirus cases since monitoring began in 1994, as confirmed by the National Microbiology Laboratory in Winnipeg.
Treatment for hantavirus focuses on managing symptoms like fever, muscle pain, nausea, and respiratory difficulties associated with hantavirus pulmonary syndrome. Medical interventions such as fluid replacement, oxygen therapy, and ventilation can help alleviate symptoms. Despite ongoing research, there is currently no vaccine for hantavirus.
Various organizations are actively engaged in hantavirus vaccine development, including biotechnology companies and research institutions. The process involves testing effective antigens on rodents to establish immunity without adverse effects. While progress is being made, the timeline for a vaccine rollout remains uncertain.
The development of hantavirus vaccines has historically faced challenges due to limited commercial interest and funding. However, ongoing research initiatives aim to address this gap and advance vaccine development. Public health experts emphasize the importance of continued efforts to combat hantavirus and prevent future outbreaks.
